<DOC>
	<DOCNO>NCT01255696</DOCNO>
	<brief_summary>A phase 2a study evaluate safety efficacy ALV003 treat celiac disease .</brief_summary>
	<brief_title>Safety Efficacy Varying Methods ALV003 Administration Treatment Celiac Disease</brief_title>
	<detailed_description />
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>History biopsyproven celiac disease Adherence glutenfree diet TG2 antibody negative Signed inform consent Active dermatitis herpetiformis History IgEmediated reaction gluten Use specific medication 6 month prior entry History alcohol abuse illicit drug use Current untreated GI disease Positive pregnancy test Received experimental drug within 14 day randomization Uncontrolled chronic disease condition Uncontrolled complication celiac disease Any medical condition could adversely affect study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Celiac Disease</keyword>
	<keyword>Coeliac Disease</keyword>
	<keyword>Celiac Sprue</keyword>
	<keyword>Keliakia Disease</keyword>
</DOC>